Sector Alpha Week of 2026-07-31
Sector Alpha — machine-written from the numbers · Data as of 2026-07-31

Aequs Ltd

AEQUS
Aerospace & Defence - Equipments

Aequs Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is already 13 weeks into its uptrend — timing risk, not thesis risk.

The price is in a confirmed uptrend (13 weeks in). Underneath, the last four quarters read deteriorating — profit −1,425.0% year on year. What settles it: the next one or two quarters of delivery.

Price
₹229
Revenue (Jun 26)
₹396 Cr
+54.7% YoY
Profit (Jun 26)
₹−53.0 Cr
−1,425.0% YoY
Operating margin
3.7%
−7.3 pp YoY
ROCE
2%
FY26
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Aequs Ltd trades at ₹229, in a confirmed uptrend and 13 weeks into that stage. That is +27.5% against its own 200-day average. It sits at 85% of a 52-week range of ₹117 to ₹249. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks.

Today the stock is in a confirmed uptrend — week 13 of stage 2, confirmed. At ₹229 it trades +27.5% versus its 200-day average and sits at 85% of its 52-week range (₹117–₹249).

Jul 26: ₹229 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
+27.5% versus the 200-day line, week 13 of stage 2
Price50-day avg200-day avg
S4S2₹259₹221₹183₹145₹106₹229₹180Dec 25Feb 26Apr 26Jun 26Jul 26
S4S2₹259₹221₹183₹145₹106₹229₹180Dec 25Apr 26Jul 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (40 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Dec 25Jul 26

Against the market, two honest reads. Cumulative: over the last 7 months the stock moved +56% while the NIFTY 500 moved +0% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 23 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

P/E does not price Aequs Ltd — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Aequs Ltd at 12.5× its FY26 revenue of ₹1,230 Cr.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

P/E
earnings negative
PEG
n/m
not derivable — 3-year earnings growth unavailable

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Aequs Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.

Growth, year by year: revenue +33.0% in FY26 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoY
36%25%14%3.7%−7.1%%33%FY23FY24FY26
36%25%14%3.7%−7.1%%33%FY23FY24FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
RevenueProfit
55%−298.8%53%−299.4%51%−300.0%49%−300.6%47%−301.2%%%54.7%−300%Dec 24Sep 25Jun 26
55%−298.8%53%−299.4%51%−300.0%49%−300.6%47%−301.2%%%54.7%−300%Dec 24Sep 25Jun 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
2.9%2.5%2.1%1.7%1.3%%1.4%Dec 24Mar 25Sep 25Dec 25Jun 26
2.9%2.5%2.1%1.7%1.3%%1.4%Dec 24Sep 25Jun 26
ROCE
Stuck low
latest 1.4% · span 1.4%–2.8%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+33.0%+14.8%
Revenue YoY (Jun 26)
+54.7%
latest quarter vs a year ago
Profit YoY (Jun 26)
−1,425.0%
latest quarter vs a year ago
Revenue 10y
14.8%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

36.4/100 — rank 18 of 24 in Aerospace & Defence - Equipments · 51% evidence confidence

Aequs Ltd scores 36.4 out of 100 against the 24 companies it is compared with in Aerospace & Defence - Equipments, ranking 18. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 15.1 + 1.3 + 10 + 10 = 36.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Aequs Ltd reported ₹396 Cr of revenue in the Jun 26 quarter, +54.7% year on year. That is the 3rd straight quarter of year-on-year growth. Over 3 years it has compounded at 14.8% a year. The last full year, FY26, came in at ₹1,230 Cr. The last four reported quarters add to ₹1,371 Cr.

FY26 revenue came in at ₹1,230 Cr (+33.0% on the year), capping 3 years at 14.8% compound. The latest quarter (Jun 26) printed ₹396 Cr, +54.7% year on year — the 3rd consecutive quarter of year-over-year growth.

FY26 revenue ₹1,230 Cr (+33.0% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 4-year window. A bar is red when it is lower than the year before.
14.8% a year over 3 years
RevenueYoY growth
1.3k36%99625%66414%3323.7%0−7.1%₹ Cr%₹1,23033%FY23FY24FY26
1.3k36%99625%66414%3323.7%0−7.1%₹ Cr%₹1,23033%FY23FY24FY26
Jun 26: ₹396 Cr (+54.7% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
3rd straight quarter of growth
Revenue (quarterly)YoY growth
42855%32153%21451%10749%047%₹ Cr%₹39654.7%Dec 24Sep 25Jun 26
42855%32153%21451%10749%047%₹ Cr%₹39654.7%Dec 24Sep 25Jun 26

Pace check: the last four quarters averaged +51.0% growth against the decade's 14.8% — the current year is running faster than its own long-run rate.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Aequs Ltd's operating margin is 3.7% in the Jun 26 quarter, −7.3 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 4.9% to 13.0%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 3.7%, −7.3 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 4.9%–13.0%.

🚨 Why the margin moved: operating margin went −6.9 pp year on year while gross margin went −1.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY26: 7.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 4-year window.
within a 4.9–13.0% band over 4 years
operating marginYoY change (pp)
14%9.1%11%5.6%8.9%2.0%6.6%−1.5%4.3%−5.0%%%7%−2%FY23FY24FY26
14%9.1%11%5.6%8.9%2.0%6.6%−1.5%4.3%−5.0%%%7%−2%FY23FY24FY26
Jun 26: 3.7% operating margin (−7.3 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
12%6.8%8.9%2.6%6.0%−1.7%3.2%−5.9%0.3%−10%%%3.7%−7.3%Dec 24Sep 25Jun 26
12%6.8%8.9%2.6%6.0%−1.7%3.2%−5.9%0.3%−10%%%3.7%−7.3%Dec 24Sep 25Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Aequs Ltd posted a net loss of ₹53.0 Cr in the Jun 26 quarter. The full FY26 year was a loss of ₹113 Cr. That loss is 13.4% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr.

Jun 26 profit was ₹−53.0 Cr, −1,425.0% year on year. On the full year, FY26 printed ₹−113 Cr (null).

FY26 profit ₹−113 Cr (null YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 4-year window. A bar is red when it is lower than the year before.
Net profit
9−24−57−89−122₹ Cr₹−113FY23FY24FY26
9−24−57−89−122₹ Cr₹−113FY23FY24FY26
Jun 26: ₹−53.0 Cr (−1,425.0% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
14−642%−4−852%−23−1,063%−41−1,273%−59−1,483%₹ Cr%₹−53−1,425%Dec 24Sep 25Jun 26
14−642%−4−852%−23−1,063%−41−1,273%−59−1,483%₹ Cr%₹−53−1,425%Dec 24Sep 25Jun 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Aequs Ltd's cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was ₹−99.0 Cr of operating cash against ₹−113 Cr of profit. After ₹367 Cr of capital spending, ₹−466 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY26: operating cash of ₹−99.0 Cr against reported profit of ₹−113 Cr, leaving free cash of ₹−466 Cr after ₹367 Cr of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹−99.0 Cr vs profit ₹−113 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 4-year window, annual resolution. FY24/FY26 reflects an acquisition year — point shown clipped.
Operating cashNet profitFree cash
41−13−68−123−177₹ Cr₹−99₹−113₹−162FY23FY24FY26
41−13−68−123−177₹ Cr₹−99₹−113₹−162FY23FY24FY26
FY26: CFO = Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash.
of profit
100%
101.2%100.6%100.0%99.4%98.8%%FY23FY24FY26
101.2%100.6%100.0%99.4%98.8%%FY23FY24FY26

Router verdict: the bigger cash user is investment — capital spending ran 2.3× depreciation over three years, so the next section's job is to check what that build-out is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Aequs Ltd's cash conversion cycle runs 259 days in FY26, up from 146 days in FY23. Capital spending ran ₹812 Cr over the last 3 years. At FY26 sales of ₹1,230 Cr each day of that cycle holds about ₹3.4 Cr, so roughly ₹873 Cr sits inside the business at any moment.

FY26: debtors at 78 days, inventory at 419 days — roughly 13.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 259 days, looser than FY23's 146.

The full loop: cash goes out to suppliers and production on day 0; stock waits 419 days to sell; customers pay about 78 days after that; and suppliers themselves are paid at 238 days — netting out to the 259-day cycle.

In money terms: at FY26 sales of ₹1,230 Cr, each day of the cycle holds about ₹3.4 Cr — so the 259-day loop keeps roughly ₹873 Cr sitting inside the business at any moment.

FY26: a 259-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 4-year window.
+113 days vs FY23
Cash cycleInventory daysDebtor daysPayable days
45034223412618days259d419d78d238dFY23FY24FY26
45034223412618days259d419d78d238dFY23FY24FY26

On the investment side: capital spending of ₹812 Cr over the last 3 fiscal years against ₹349 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹79.0 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹367 Cr, work-in-progress ₹79.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
4273202131070₹ Cr₹367₹79FY24FY25FY26
4273202131070₹ Cr₹367₹79FY24FY25FY26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Aequs Ltd earns a ROCE of 2% in FY26. That is up from a trough of 1% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −9.2% net margin on 0.46× asset turns.

FY26 ROCE is 2%, recovered from a FY25 trough of 1% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): −9.2% net margin × 0.46× asset turns × 1.81× balance-sheet leverage ≈ −7.7% on equity. Margin does its share; leverage is a meaningful part of the equation.

FY26: ROCE 2% Return on capital employed by fiscal year, % (line). 3-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY25's 1%
ROCEWACC
13%9.7%6.5%3.3%0.0%%2%FY24FY25FY26
13%9.7%6.5%3.3%0.0%%2%FY24FY25FY26
Q4 FY26: ROCE −2.5% (TTM) Trailing-twelve-month ROCE, per quarter, %. Last 5 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)
−1.3%−1.7%−2.0%−2.3%−2.7%%−2.5%Q4 FY25Q2 FY26Q4 FY26
−1.3%−1.7%−2.0%−2.3%−2.7%%−2.5%Q4 FY25Q2 FY26Q4 FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Aequs Ltd carries total debt of ₹701 Cr against shareholder equity of ₹1,486 Cr as of Mar 26, a debt-to-equity of 0.47. On the annual view that ratio went from 1.10 in FY25 to 0.47 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹701 Cr against shareholder equity of ₹1,486 Cr — a debt-to-equity of 0.47. On the annual view, debt-to-equity went from 1.10 (FY25) to 0.47 (FY26). Read the returns on this page with that leverage in mind.

FY26: debt ₹701 Cr at 0.47× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 2-year window.
Total debtDebt-to-equity
8481.2×6361.0×4240.8×2120.6×00.4×₹ Cr×₹7010.47×FY25FY26
8481.2×6361.0×4240.8×2120.6×00.4×₹ Cr×₹7010.47×FY25FY26
Mar 26: debt ₹701 Cr, debt-to-equity 0.47 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 6 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
9391.2×7041.0×4690.8×2350.6×00.4×₹ Cr×₹7010.47×Jun 24Jun 25Mar 26
9391.2×7041.0×4690.8×2350.6×00.4×₹ Cr×₹7010.47×Jun 24Jun 25Mar 26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Aequs Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — .

A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 3 quarters.
PromotersForeign inst.Domestic inst.Public
64%48%31%15%0.0%%59.1%5.2%8.8%24.6%Dec 25Mar 26Jun 26
64%48%31%15%0.0%%59.1%5.2%8.8%24.6%Dec 25Mar 26Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Aequs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Aerospace & Defence - Equipments
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Sigma Advanced System LtdSIGMAADV 72.6/100Favorable setup93% evidence LEADER 24.0/35 Revenue 100% · PAT 100% · OPM change -12 pp 83% evidence 16.6/25 ROCE 60.8% · OPM 17% 95% evidence 12.0/20 P/E 42.6× · PEG 2.35 100% evidence 20.0/20 RS sector 105.2% · RS bench 142.5% · 1Y 494.4%12 of 12 weeks ahead 100% evidence
Exact sum: 24 + 16.6 + 12 + 20 = 72.6 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Sika Interplant Systems LtdSIKA 72.6/100Favorable setup90% evidence TURNING 28.4/35 Revenue 43% · PAT 38.1% · OPM change 7.9 pp 88% evidence 21.9/25 ROCE 34.6% · OPM 25.2% 100% evidence 12.9/20 P/E 67.4× · PEG 1.01 100% evidence 9.4/20 RS sector -10.2% · RS bench 6% · 1Y -1.7%3 of 7 weeks ahead 70% evidence
Exact sum: 28.4 + 21.9 + 12.9 + 9.4 = 72.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Astra Microwave Products LtdASTRAMICRO 70.5/100Favorable setup96% evidence LEADER 21.0/35 Revenue 10.6% · PAT 27% · OPM change 4 pp 88% evidence 19.4/25 ROCE 20.2% · OPM 33% 100% evidence 10.8/20 P/E 91.6× · PEG 1.19 100% evidence 19.3/20 RS sector 30.4% · RS bench 61.4% · 1Y 90.9%12 of 12 weeks ahead 100% evidence
Exact sum: 21 + 19.4 + 10.8 + 19.3 = 70.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Paras Defence and Space Technologies LtdPARAS 66.4/100Favorable setup78% evidence LEADER 21.8/35 Revenue 30.4% · PAT 43.5% · OPM change -1 pp 83% evidence 16.8/25 ROCE 16.9% · OPM 25% 76% evidence 9.2/20 P/E 118× · PEG — 50% evidence 18.6/20 RS sector 27.1% · RS bench 57.1% · 1Y 60.5%12 of 12 weeks ahead 100% evidence
Exact sum: 21.8 + 16.8 + 9.2 + 18.6 = 66.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5MTAR Technologies LtdMTARTECH 63.2/100Mixed-positive evidence90% evidence FADING 30.7/35 Revenue 53.5% · PAT 100% · OPM change 6 pp 100% evidence 13.9/25 ROCE 15.1% · OPM 24% 100% evidence 6.3/20 P/E 129× · PEG — 50% evidence 12.3/20 RS sector 21.9% · RS bench 44.7% · 1Y 280.8%11 of 12 weeks ahead 100% evidence
Exact sum: 30.7 + 13.9 + 6.3 + 12.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Apollo Micro Systems LtdAPOLLO 59.9/100Mixed-positive evidence96% evidence LEADER 21.9/35 Revenue 60.9% · PAT 92.9% · OPM change 1 pp 88% evidence 14.2/25 ROCE 14.5% · OPM 23% 100% evidence 7.1/20 P/E 128× · PEG 1.6 100% evidence 16.7/20 RS sector 6.5% · RS bench 32% · 1Y 126.8%12 of 12 weeks ahead 100% evidence
Exact sum: 21.9 + 14.2 + 7.1 + 16.7 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Vinyas Innovative Technologies LtdVINYAS 59.3/100Thin evidence · provisional57% evidence TURNING 21.7/35 Revenue 65% · PAT 100% · OPM change 3 pp 48% evidence 18.5/25 ROCE 21.4% · OPM 13% 95% evidence 10.9/20 P/E 51.1× · PEG — 15% evidence 8.2/20 RS sector -17.5% · RS bench 6% · 1Y -6.9%10 of 11 weeks ahead 70% evidence
Exact sum: 21.7 + 18.5 + 10.9 + 8.2 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Data Patterns (India) LtdDATAPATTNS 58.1/100Mixed-positive evidence100% evidence FADING 21.5/35 Revenue 33.9% · PAT 24.2% · OPM change -5 pp 100% evidence 18.6/25 ROCE 21.9% · OPM 27% 100% evidence 5.0/20 P/E 88.7× · PEG 3.94 100% evidence 13.0/20 RS sector 5% · RS bench 30.1% · 1Y 59.9%11 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 18.6 + 5 + 13 = 58.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
9Azad Engineering LtdAZAD 57.4/100Mixed-positive evidence89% evidence FADING 24.5/35 Revenue 32.2% · PAT 54% · OPM change 2 pp 88% evidence 12.9/25 ROCE 11.9% · OPM 38% 100% evidence 8.0/20 P/E 111× · PEG 2.29 65% evidence 12.0/20 RS sector 1.6% · RS bench 27% · 1Y 47.5%11 of 12 weeks ahead 100% evidence
Exact sum: 24.5 + 12.9 + 8 + 12 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Ideaforge Technology LtdIDEAFORGE 57.1/100Mixed-positive evidence68% evidence LEADER 24.6/35 Revenue 41% · PAT 71.4% · OPM change 152 pp 65% evidence 4.6/25 ROCE -2.8% · OPM 44% 100% evidence 10.0/20 P/E — · PEG — 0% evidence 17.9/20 RS sector 25.6% · RS bench 53.6% · 1Y 85.5%12 of 12 weeks ahead 100% evidence
Exact sum: 24.6 + 4.6 + 10 + 17.9 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Hindustan Aeronautics LtdHAL 56.2/100Mixed-positive evidence96% evidence BREAKING OUT 11.0/35 Revenue 6.8% · PAT 9% · OPM change -3 pp 88% evidence 21.1/25 ROCE 32% · OPM 36% 100% evidence 15.2/20 P/E 34.1× · PEG 1.18 100% evidence 8.9/20 RS sector -18.6% · RS bench 4% · 1Y 2.1%8 of 12 weeks ahead 100% evidence
Exact sum: 11 + 21.1 + 15.2 + 8.9 = 56.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
12Rossell Techsys LtdROSSTECH 54.1/100Mixed-positive evidence83% evidence FADING 29.0/35 Revenue 82.9% · PAT 68.8% · OPM change 1.8 pp 100% evidence 7.4/25 ROCE 11.5% · OPM 14.4% 100% evidence 9.0/20 P/E 136× · PEG — 15% evidence 8.7/20 RS sector -3.2% · RS bench 20.7% · 1Y 64.3%9 of 12 weeks ahead 100% evidence
Exact sum: 29 + 7.4 + 9 + 8.7 = 54.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Jaykay Enterprises LtdJAYKAY 49.0/100Mixed-negative evidence62% evidence ASLEEP 25.8/35 Revenue 100% · PAT 100% · OPM change 34 pp 62% evidence 6.8/25 ROCE 8.2% · OPM -10% 95% evidence 11.5/20 P/E 32.6× · PEG — 15% evidence 4.9/20 RS sector -20.9% · RS bench -6.2% · 1Y 20.6%6 of 10 weeks ahead 70% evidence
Exact sum: 25.8 + 6.8 + 11.5 + 4.9 = 49 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -20.9% and the one-year return is 20.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
14Mishra Dhatu Nigam LtdMIDHANI 45.7/100Mixed-negative evidence96% evidence FADING 16.3/35 Revenue 12.6% · PAT 18.9% · OPM change -2 pp 88% evidence 13.7/25 ROCE 11.3% · OPM 21% 100% evidence 7.4/20 P/E 56.4× · PEG 5.62 100% evidence 8.3/20 RS sector -16.9% · RS bench 5.1% · 1Y -2%10 of 12 weeks ahead 100% evidence
Exact sum: 16.3 + 13.7 + 7.4 + 8.3 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Dynamatic Technologies LtdDYNAMATECH 43.8/100Mixed-negative evidence89% evidence FADING 16.2/35 Revenue 15.5% · PAT -23.3% · OPM change 1 pp 88% evidence 10.2/25 ROCE 10% · OPM 11% 100% evidence 10.3/20 P/E 140× · PEG 1.42 65% evidence 7.1/20 RS sector -12.3% · RS bench 10.4% · 1Y 47.5%4 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 10.2 + 10.3 + 7.1 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Zen Technologies LtdZENTEC 41.9/100Mixed-negative evidence69% evidence ASLEEP 5.0/35 Revenue -23.4% · PAT -27.8% · OPM change -14 pp 95% evidence 16.6/25 ROCE 16.2% · OPM 27% 76% evidence 10.5/20 P/E 80.7× · PEG — 15% evidence 9.8/20 RS sector -6.5% · RS bench 6.5% · 1Y -8.7%8 of 10 weeks ahead 70% evidence
Exact sum: 5 + 16.6 + 10.5 + 9.8 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Bharat Electronics LtdBEL 41.7/100Mixed-negative evidence100% evidence ASLEEP 14.0/35 Revenue 19.8% · PAT 11.8% · OPM change -3 pp 100% evidence 18.6/25 ROCE 36.5% · OPM 25% 100% evidence 7.3/20 P/E 46.1× · PEG 3.54 100% evidence 1.8/20 RS sector -28% · RS bench -8% · 1Y -1.9%0 of 12 weeks ahead 100% evidence
Exact sum: 14 + 18.6 + 7.3 + 1.8 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Aequs Ltdthis pageAEQUS 36.4/100Thin evidence · provisional51% evidence BREAKING OUT 15.1/35 Revenue 44.3% · PAT — · OPM change -7.3 pp 74% evidence 1.3/25 ROCE 1.6% · OPM 3.7% 100% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence
Exact sum: 15.1 + 1.3 + 10 + 10 = 36.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Avantel LtdAVANTEL 35.7/100Mixed-negative evidence77% evidence TURNING 10.1/35 Revenue -3.2% · PAT -67.2% · OPM change 4.6 pp 100% evidence 9.2/25 ROCE 9.6% · OPM 24.8% 100% evidence 8.7/20 P/E 251× · PEG — 15% evidence 7.7/20 RS sector -11.9% · RS bench 0.1% · 1Y 19%8 of 11 weeks ahead 70% evidence
Exact sum: 10.1 + 9.2 + 8.7 + 7.7 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20AXISCADES Technologies LtdAXISCADES 35.4/100Mixed-negative evidence96% evidence ASLEEP 15.4/35 Revenue 12.4% · PAT -4.3% · OPM change -1.7 pp 88% evidence 12.3/25 ROCE 15.3% · OPM 12.3% 100% evidence 4.9/20 P/E 83.6× · PEG 3.04 100% evidence 2.8/20 RS sector -21.3% · RS bench -1.3% · 1Y 13.4%6 of 12 weeks ahead 100% evidence
Exact sum: 15.4 + 12.3 + 4.9 + 2.8 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21NIBE LtdNIBE 32.4/100Adverse evidence65% evidence TURNING 9.6/35 Revenue -6.7% · PAT -80% · OPM change 3 pp 83% evidence 7.6/25 ROCE 4.8% · OPM 20% 76% evidence 8.5/20 P/E 380× · PEG — 15% evidence 6.7/20 RS sector -29.8% · RS bench 11.1% · 1Y -17%11 of 11 weeks ahead 70% evidence
Exact sum: 9.6 + 7.6 + 8.5 + 6.7 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Bharat Dynamics LtdBDL 29.4/100Adverse evidence83% evidence ASLEEP 7.6/35 Revenue -27% · PAT -23.6% · OPM change -5 pp 88% evidence 12.9/25 ROCE 13.8% · OPM 12% 100% evidence 5.0/20 P/E 109× · PEG 4.44 65% evidence 3.9/20 RS sector -22.4% · RS bench -11.8% · 1Y -24.4%2 of 10 weeks ahead 70% evidence
Exact sum: 7.6 + 12.9 + 5 + 3.9 = 29.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23BEML LtdBEML 26.3/100Adverse evidence90% evidence ASLEEP 6.5/35 Revenue 8.1% · PAT -51.5% · OPM change -11 pp 88% evidence 5.3/25 ROCE 7.7% · OPM 15% 100% evidence 9.5/20 P/E 103× · PEG 1.18 100% evidence 5.0/20 RS sector -19.9% · RS bench -6.2% · 1Y -15.6%5 of 10 weeks ahead 70% evidence
Exact sum: 6.5 + 5.3 + 9.5 + 5 = 26.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24DCX Systems LtdDCXINDIA 25.1/100Adverse evidence67% evidence ASLEEP 8.2/35 Revenue -31.4% · PAT -80% · OPM change -2 pp 83% evidence 3.4/25 ROCE 0.9% · OPM -0.2% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 3.5/20 RS sector -27% · RS bench -12.4% · 1Y -32%5 of 10 weeks ahead 70% evidence
Exact sum: 8.2 + 3.4 + 10 + 3.5 = 25.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Aequs Ltd's share price today?

Aequs Ltd trades at ₹229. The company is valued at ₹15,369 Cr. The stock sits at 85% of its 52-week range of ₹117–₹249, +27.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 13 weeks in. — as of 31 July 2026.

What were Aequs Ltd's latest quarterly results?

Aequs Ltd reported revenue of ₹396 Cr and a net loss of ₹53.0 Cr for the Jun 26 quarter. Revenue rose 54.7% and profit fell 1,425.0% year on year. Earnings per share were ₹−0.79. The operating margin was 3.7%, 7.3 pp lower than a year earlier. — as of 31 July 2026.

What is Aequs Ltd's revenue?

Aequs Ltd reported revenue of ₹396 Cr in the Jun 26 quarter, +54.7% year on year. For the full FY26 fiscal year, revenue was ₹1,230 Cr (+33.0%). Over the last 3 years revenue compounded at 14.8% a year. — as of 31 July 2026.

What is Aequs Ltd's profit?

Aequs Ltd earned ₹−53.0 Cr of net profit in the Jun 26 quarter, −1,425.0% year on year. Full-year FY26 profit was ₹−113 Cr. The operating margin ran 3.7% in the latest quarter. — as of 31 July 2026.

What is Aequs Ltd's market cap?

Aequs Ltd's market capitalisation is ₹15,369 Cr at a share price of ₹229. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.

Does Aequs Ltd pay a dividend?

No — Aequs Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.

Is Aequs Ltd growing?

Not right now — Aequs Ltd's latest numbers are shrinking: latest-quarter revenue +54.7% year on year, profit −1,425.0%, and the margin −7.3 pp at 3.7%. The earnings engine currently reads: deteriorating — as of 31 July 2026.

How is Aequs Ltd performing?

Aequs Ltd is in a confirmed uptrend, 13 weeks in. Its latest quarter's revenue rose 54.7% and profit fell 1,425.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 23 weeks. This describes what the data did, not a rating. — as of 31 July 2026.

Is Aequs Ltd in an uptrend?

Yes — the price is in a confirmed uptrend (week 13 of stage 2), trading +27.5% versus its 200-day average and at 85% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.

Is Aequs Ltd beating the market?

On recent form, yes — Aequs Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7 months the stock moved +56% against the NIFTY 500's +0% — ahead of the index over the full window. — as of 31 July 2026.

Will Aequs Ltd's share price go up?

This page publishes no price forecast for Aequs Ltd. What it measures instead: the share price is ₹229, the price is in a confirmed uptrend 13 weeks in. Direction is not something this site claims to know. — as of 31 July 2026.

Who owns Aequs Ltd?

Promoters hold 59.1% of Aequs Ltd, foreign institutions 5.2%, domestic institutions 8.8% and the public 24.6% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.

Does Aequs Ltd have too much debt?

It is moderate — Aequs Ltd's debt-to-equity is 0.47, and operating profit covers the interest bill 1×. FY26 borrowings were ₹701 Cr against equity of ₹1,487 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.

What is Aequs Ltd's capex?

Aequs Ltd spent ₹812 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹367 Cr, with ₹79.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.

What is Aequs Ltd's cash flow?

Aequs Ltd generated ₹−99.0 Cr of operating cash flow in FY26 and ₹−466 Cr of free cash flow after ₹367 Cr of capital spending. Reported profit that year was ₹−113 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.

Where is Aequs Ltd in its business cycle?

Aequs Ltd's FY26 operating margin was 7.0%, against a 4-year band of 4.9%–13.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 3.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.

What could break the Aequs Ltd story?

Biggest watch item: the price is already 13 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.

Is Aequs Ltd a stock worth studying right now?

This is not investment advice. The machine read: Aequs Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI